Dataset Information


Plasma Angiotensin II Is Increased in Critical Coronavirus Disease 2019.

ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) employs angiotensin-converting enzyme 2 (ACE2) as its receptor for cell entrance, and studies have suggested that upon viral binding, ACE2 catalytic activity could be inhibited; therefore, impacting the regulation of the renin-angiotensin-aldosterone system (RAAS). To date, only few studies have evaluated the impact of SARS-CoV-2 infection on the blood levels of the components of the RAAS. The objective of this study was to determine the blood levels of ACE, ACE2, angiotensin-II, angiotensin (1-7), and angiotensin (1-9) at hospital admission and discharge in a group of patients presenting with severe or critical evolution of coronavirus disease 2019 (COVID-19). We showed that ACE, ACE2, angiotensin (1-7), and angiotensin (1-9) were similar in patients with critical and severe COVID-19. However, at admission, angiotensin-II levels were significantly higher in patients presenting as critical, compared to patients presenting with severe COVID-19. We conclude that blood levels of angiotensin-II are increased in hospitalized patients with COVID-19 presenting the critical outcome of the disease. We propose that early measurement of Ang-II could be a useful biomarker for identifying patients at higher risk for extremely severe progression of the disease.

PROVIDER: S-EPMC9263116 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC7937723 | BioStudies
| S-EPMC7346797 | BioStudies
| S-EPMC7377983 | BioStudies
| S-EPMC7426477 | BioStudies
| S-EPMC8166347 | BioStudies
| S-EPMC7191628 | BioStudies
| S-EPMC8198473 | BioStudies
| S-EPMC9238740 | BioStudies
| S-EPMC8015242 | BioStudies
| S-EPMC7444473 | BioStudies